Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables - Net: 2013-2025

Historic Receivables - Net for Coherus Oncology (CHRS) over the last 9 years, with Sep 2025 value amounting to $9.2 million.

  • Coherus Oncology's Receivables - Net fell 94.48% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 94.48%. This contributed to the annual value of $111.3 million for FY2024, which is 57.27% down from last year.
  • As of Q3 2025, Coherus Oncology's Receivables - Net stood at $9.2 million, which was up 80.96% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Receivables - Net registered a high of $260.5 million during Q4 2023, and its lowest value of $5.1 million during Q2 2025.
  • Its 3-year average for Receivables - Net is $136.4 million, with a median of $141.3 million in 2023.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 148.33% in 2024, then slumped by 97.08% in 2025.
  • Over the past 5 years, Coherus Oncology's Receivables - Net (Quarterly) stood at $123.0 million in 2021, then dropped by 10.61% to $110.0 million in 2022, then soared by 136.92% to $260.5 million in 2023, then slumped by 57.27% to $111.3 million in 2024, then tumbled by 94.48% to $9.2 million in 2025.
  • Its Receivables - Net stands at $9.2 million for Q3 2025, versus $5.1 million for Q2 2025 and $60.5 million for Q1 2025.